Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8506 to 8520 of 8908 results

  1. COVID-19 rapid evidence summary: Tocilizumab for COVID-19 (ES33)

    This guideline has been updated and replaced by NICE COVID-19 rapid guideline NG191.

  2. COVID-19 rapid evidence summary: Sarilumab for COVID-19 (ES34)

    This guideline has been updated and replaced by NICE COVID-19 rapid guideline NG191.

  3. Daylight for treating generalised anxiety disorder in adults (MIB309)

    August 2023: This medtech innovation briefing (MIB) has been withdrawn at the company’s request as the evidence for the technology has moved on and the company expect to seek a NICE guidance output in due course.

  4. Ventripoint Medical System Plus for measuring heart volume and function (MIB310)

    February 2023: The medtech innovation briefing on Ventripoint Medical System Plus for measuring heart volume and function has been withdrawn as the company have withdrawn from the process.

  5. BPMpathway for rehabilitation support in joint replacement surgery (MIB319)

    MIB319 BPMpathway for rehabilitation support in joint replacement surgery has been withdrawn. This is because factual inaccuracies have been identified. NHS England no longer fund NICE to produce or maintain medtech innovation briefings, therefore these are no longer being reviewed.

  6. Flow transcranial direct current stimulation for treating depression (MIB324)

    May 2024: This medtech innovation briefing has been withdrawn. This is because the evidence for the technology has changed since it was published. NHS England no longer funds NICE to produce or maintain medtech innovation briefings, so these are no longer being reviewed.

  7. Episcissors-60 for guided mediolateral episiotomy (MIB33)

    This advice has been updated and replaced by NICE medical technologies guidance 47.

  8. The BCM – Body Composition Monitor for managing fluid in people having dialysis (MIB41)

    This advice has been updated and replaced by NICE guidance HTG441 

  9. Elivaldogene autotemcel for treating cerebral adrenoleukodystrophy [ID1284]

    Discontinued Reference number: GID-HST10038

  10. Drisapersen for the first-line treatment of Duchenne's muscular dystrophy [ID911]

    Discontinued Reference number: GID-HST10004